Abstract 3170: AKT/mTOR pharmacologic inhibition sensitizes RAS/MAPK-activated neuroblastoma cells to MEK1/2 inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-3170
Abstract: Relapsed neuroblastoma tumors have an increased incidence of activating mutations in the RAS/MAPK pathway. Pre-clinical studies indicate these tumors have an increased sensitivity to inhibitors of the RAS/MAPK pathway but single-agent therapeutic approaches have rarely… read more here.
Keywords: mek1 inhibitors; tram; inhibition; cell ... See more keywords
Abstract 2000: Cancer metastasis driven by the novel MEK1 substrate MACC1 is restricted by clinically applicable MEK1 inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Tumor Biology"
DOI: 10.1158/1538-7445.am2019-2000
Abstract: Cancer metastasis is responsible for >90% of cancer deaths and remains a major treatment challenge. In search of new drivers of metastasis we identified the novel, previously undescribed gene Metastasis-Associated in Colon Cancer 1 (MACC1)… read more here.
Keywords: metastasis; cancer; mek1 inhibitors; macc1 ... See more keywords